Jetstream Venture Fund (Jetstream), an innovative interval fund dedicated to opening access to institutional-grade deal flow for a wider mainstream audienc...
Rapidly Advancing Five IRD Programs with Four Clinical Data Readouts Expected in 2027 RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing o...
Regulatory milestone underscores opportunity for shared regulatory-science and evidence frameworks to support the next generation of therapies. Critical...
Hillhurst Biopharmaceuticals Inc. ("Hillhurst Bio"), a clinical-stage biopharmaceutical company focused on developing novel oral liquid drug products bas...
Target-specific licensing agreement enabling Antharis to advance proprietary dual-payload antibody-drug conjugate (ADC) progra...
Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advanci...
Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual ...
The expanded partnership adds Denmark, Finland, Norway and Sweden to GENESIS Pharma’s existing network of thirteen Southeast European markets. ...
Anocca AB (‘Anocca’ or the ‘Company’), a clinical-stage biotechnology company developing advanced T-cell immunotherapies, announc...
New registry will generate robust real-world evidence on disease burden, treatment patterns and long-term effectiveness of newly approved and emerging th...
Clinical Trial approval for TCX-001 is another significant development milestone for T-CURX and marks the transition of T-CURX from a pre-clinical to a...
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on autoimmune and inflammatory dise...
Leading regenerative medicine innovators unite to deliver seamless stem cell banking and personalized biologic solutions for physicians and patients nati...
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics...
© 2026 Biopharma Boardroom. All Rights Reserved.
